Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 18/20 | 0.42 |
| ▸ | PPARG | P37231 | 14/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.34 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.34 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.34 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.34 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.34 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5226585 | 0.87 | PPARA (0.44) | PPARAPPARGFFAR1 | |
| SCHEMBL5441659 | 0.85 | PPARA (0.43) | PPARAPPARGFFAR1 | |
| SCHEMBL5260637 | 0.78 | PPARG (0.45) | PPARAPPARGFFAR1 | |
| SCHEMBL5229697 | 0.65 | PPARA (0.52) | PPARAPPARGFFAR1 | |
| SCHEMBL5225055 | 0.64 | PPARA (0.51) | PPARAPPARGFFAR1 | |
| SCHEMBL5439723 | 0.64 | TP53 (0.47) | PPARAPPARGFFAR1 | |
| SCHEMBL5262265 | 0.63 | PPARG (0.46) | PPARAPPARGFFAR1 | |
| SCHEMBL5439213 | 0.63 | PPARG (0.45) | PPARAPPARGFFAR1 | |
| SCHEMBL17047828 | 0.61 | PPARA (0.36) | PPARAPPARGFFAR1 | |
| SCHEMBL17047838 | 0.61 | PPARA (0.36) | PPARAPPARGFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254882-A1 | Sulfamide Derivatives and Pharmaceutical Composition for Upregulation of Lipid Metabolism Comprising Same | CRYSTAL GENOMICS, INC. (KR) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254882-A1 | Sulfamide Derivatives and Pharmaceutical Composition for Upregulation of Lipid Metabolism Comprising Same | SULT2A1, SPTLC2, SGMS2 | PPARA 190/4885PPARG 399/4885FFAR1 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.